Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 94

Similar articles for PubMed (Select 16939544)

1.

Rosiglitazone is effective and well-tolerated in a range of therapeutic regimens during daily practice in patients with type 2 diabetes.

Rosak C, Standl E, Reblin T, Stammer H, Seidel DK.

Int J Clin Pract. 2006 Sep;60(9):1040-7.

PMID:
16939544
2.

Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with Type 2 diabetes inadequately controlled on metformin alone.

Hamann A, Garcia-Puig J, Paul G, Donaldson J, Stewart M.

Exp Clin Endocrinol Diabetes. 2008 Jan;116(1):6-13. Epub 2007 Dec 20.

PMID:
18095238
4.
5.

Rosiglitazone plus metformin is effective and well tolerated in clinical practice: results from large observational studies in people with type 2 diabetes.

Rosak C, Petzoldt R, Wolf R, Reblin T, Dehmel B, Seidel D.

Int J Clin Pract. 2005 Oct;59(10):1131-6.

PMID:
16178978
6.

Initial treatment with fixed-dose combination rosiglitazone/glimepiride in patients with previously untreated type 2 diabetes.

Chou HS, Palmer JP, Jones AR, Waterhouse B, Ferreira-Cornwell C, Krebs J, Goldstein BJ.

Diabetes Obes Metab. 2008 Aug;10(8):626-37. Epub 2007 Jul 21.

PMID:
17645558
7.

Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study.

Rosenstock J, Goldstein BJ, Vinik AI, O'neill MC, Porter LE, Heise MA, Kravitz B, Dirani RG, Freed MI; RESULT Study Group.

Diabetes Obes Metab. 2006 Jan;8(1):49-57.

PMID:
16367882
8.

Potential benefits of early addition of rosiglitazone in combination with glimepiride in the treatment of type 2 diabetes.

Rosenstock J, Chou HS, Matthaei S, Seidel DK, Hamann A.

Diabetes Obes Metab. 2008 Sep;10(10):862-73. doi: 10.1111/j.1463-1326.2007.00815.x. Epub 2008 Jan 14.

PMID:
18201206
9.
10.

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG.

Clin Ther. 2008 Aug;30(8):1448-60. doi: 10.1016/j.clinthera.2008.08.006. Erratum in: Clin Ther. 2008 Oct;30(10):1937.

PMID:
18803987
11.

Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone.

Raskin P, McGill J, Saad MF, Cappleman JM, Kaye W, Khutoryansky N, Hale PM; Repaglinide/Rosiglitazone Study Group.

Diabet Med. 2004 Apr;21(4):329-35.

PMID:
15049934
12.

A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes.

Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J; Rosiglitazone Clinical Trials Study Group.

Diabetes Care. 2001 Jul;24(7):1226-32.

PMID:
11423507
13.

Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy.

Garber A, Klein E, Bruce S, Sankoh S, Mohideen P.

Diabetes Obes Metab. 2006 Mar;8(2):156-63.

PMID:
16448519
14.
15.

Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study.

Weissman P, Goldstein BJ, Rosenstock J, Waterhouse B, Cobitz AR, Wooddell MJ, Strow LJ.

Curr Med Res Opin. 2005 Dec;21(12):2029-35.

PMID:
16368054
17.

Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.

Triplitt C, Glass L, Miyazaki Y, Wajcberg E, Gastaldelli A, De Filippis E, Cersosimo E, DeFronzo RA.

Diabetes Care. 2006 Nov;29(11):2371-7.

PMID:
17065670
18.

Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts).

Raskin P, Matfin G, Schwartz SL, Chaykin L, Chu PL, Braceras R, Wynne A.

Diabetes Obes Metab. 2009 Jan;11(1):27-32. Epub 2007 Oct 17.

PMID:
17941873
19.

Effect of metformin plus roziglitazone compared with metformin alone on glycaemic control in well-controlled Type 2 diabetes.

Stewart MW, Cirkel DT, Furuseth K, Donaldson J, Biswas N, Starkie MG, Phenekos C, Hamann A.

Diabet Med. 2006 Oct;23(10):1069-78.

PMID:
16978370
20.

Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.

Ushakova O, Sokolovskaya V, Morozova A, Valeeva F, Zanozina O, Sazonova O, Zhadanova E, Starceva M, Kazakova E, Saifullina M, Shapiro I, Tarasov A, Al-Tayar B, Starkova N.

Clin Ther. 2007 Nov;29(11):2374-84.

PMID:
18158078
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk